Clincosm LogoSign in Get a demo

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Sponsor
MediciNova (Industry)
Overall Status
Completed
CT.gov ID
NCT03533387
Collaborator
(none)
28
Enrollment
1
Location
3
Arms
5.7
Actual Duration (Months)
5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

Part 1:

To compare the bioavailability and pharmacokinetic profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers; and To choose one of the two MN-166 50mg ER tablet formulations for evaluation in Part 2.

Secondary: To determine the safety and tolerability of the two formulations of MN-166 ER tablets in a single-dose regimen in healthy volunteers.

Part 2:

To compare the bioavailability and steady-state pharmacokinetic profile of MN-166 50mg ER tablet with MN-166 10mg capsules in a multiple-dose regimen in healthy volunteers; and

Secondary: To determine the safety and tolerability of MN-166 ER tablets in a multiple-dose regimen in healthy volunteers

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Subjects will receive the following three treatments in a crossover fashion, administered one week apart: ER1: Single dose (50mg) of ER Prototype 1 (one 50mg ER1 tablet), ER2: Single dose (50mg) of ER Prototype 2 (one 50mg ER2 tablet), and IR: Two doses of intermediate-release capsules (50mg Pinatos® capsules in two divided doses 12 hours apart, i.e., 25mg for each dose).Subjects will receive the following three treatments in a crossover fashion, administered one week apart:ER1: Single dose (50mg) of ER Prototype 1 (one 50mg ER1 tablet), ER2: Single dose (50mg) of ER Prototype 2 (one 50mg ER2 tablet), and IR: Two doses of intermediate-release capsules (50mg Pinatos® capsules in two divided doses 12 hours apart, i.e., 25mg for each dose).
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Bioequivalence Study of Two MN-166 (Ibudilast) 50 mg Extended Release Tablet Formulations Compared With MN-166 (Ibudilast) 10mg Capsules in Healthy Volunteers
Actual Study Start Date :
Apr 11, 2018
Actual Primary Completion Date :
Jul 6, 2018
Actual Study Completion Date :
Sep 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Extended-release formulation 1 (ER1)

50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.

Drug: MN-166
an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
Other Names:
  • ibudilast
  • Pinatos® capsule

    		•
    Experimental: Extended-release formulation 2 (ER2)

    50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.

    Drug: MN-166
    an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
    Other Names:
  • ibudilast
  • Pinatos® capsule

    		•
    Active Comparator: Intermediate-release formulation (IR)

    10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.

    Drug: MN-166
    an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
    Other Names:
  • ibudilast
  • Pinatos® capsule

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Compare the PK Profile of two new formulations in Single-day dose of MN-166 [5 weeks]

      Compare the maximum plasma concentrations [Cmax] of MN-166 of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers.

    Secondary Outcome Measures

    1. Compare the incidence of treatment-emergent adverse events of two new formulations in Single-day dose of MN-166 [5 weeks]

      Compare the number and frequency of treatment-emergent adverse events (serious and non-serious) profiles of two different formulations MN-166 50mg, extended release (ER) tablets with MN-166 10mg capsules in a single-dose regimen in healthy volunteers.

    2. Compare the PK Profile of two new formulations in Multi-day dose of MN-166 [3 weeks]

      Compare the maximum plasma concentrations [Cmax] of MN-166 of two different formula in a multiple-dose regimen.

    3. Compare the incidence of treatment-emergent adverse events of two new formulations in Multi-day dose of MN-166 [3 weeks]

      Compare the number and frequency of treatment-emergent adverse events (serious and non-serious) of MN-166 (pharmacokinetic profiles) of two different formula in a multiple-dose regimen.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    1. Able to provide written informed consent.

    2. Healthy non-smoking male and female subjects aged 18 to 65 years, inclusive.

    3. No clinical abnormalities in laboratory and urine analyses.

    4. Normal renal function (GFR > 90mL/min).

    5. Liver enzymes should be less than twice the upper limit of normal (ULN).

    6. Screening electrocardiogram (ECG) with QT interval adjusted for heart rate within normal limits.

    7. Agree to use barrier contraceptive methods during the course of the study (hormonal contraceptive alone is not acceptable).

    8. Females of child-bearing potential must have a negative pregnancy test on Study Day 1.

    Exclusion Criteria:

    1. Known hypersensitivity to Pinatos® or its components.

    2. Condition(s) which might affect drug absorption, metabolism or excretion.

    3. Untreated mental illness, current drug addiction or abuse or alcoholism.

    4. Donated blood in the past 90 days or have poor peripheral venous access.

    5. Platelets < l00,000/mm3, history of thrombocytopenia.

    6. Confirmed diagnosis of chronic liver disease, e.g., chronic Hep. B, Hep. C infection, auto-immune, alcoholic or neoplastic liver disease.

    7. Positive serostatus for HIV.

    8. Currently pregnant or nursing.

    9. History of clinically significant cardiovascular, pulmonary, endocrine, neurological, metabolic, or psychiatric diseases.

    10. Received an investigational drug in the past 30 days.

    11. Unable to swallow tablets.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 WCCT Global, Inc. Cypress California United States 90630

    Sponsors and Collaborators

    • MediciNova

    Investigators

    • Principal Investigator: Robina Smith, MD, WCCT Global, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    MediciNova
    ClinicalTrials.gov Identifier:
    NCT03533387
    Other Study ID Numbers:
    • MN-166-HDT-001
    First Posted:
    May 23, 2018
    Last Update Posted:
    May 31, 2019
    Last Verified:
    May 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Ibudilast

    Study Results

    No Results Posted as of May 31, 2019